LOGIN  |  REGISTER
Terns Pharmaceuticals
Chimerix

Waystar Reports Second Quarter 2024 Results

August 07, 2024 | Last Trade: US$27.72 0.30 1.09
  • Revenue growth of 20% year-over-year
  • Net loss of $27.7 million and non-GAAP net income of $5.0 million
  • Net loss margin of (11.8)%; Adjusted EBITDA margin of 40%

LEHI, Utah and LOUISVILLE, Ky., Aug. 7, 2024 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today reported results for the three-month period ended June 30, 2024.

"Waystar delivered strong performance across all key metrics in Q2," said Matt Hawkins, Chief Executive Officer of Waystar. "We have solid momentum as clients utilize the cloud-based Waystar software platform, which we have purpose-built to drive client return on investment and a differentiated, modern user experience."

Hawkins continued, "There is meaningful opportunity ahead of us, as the demand for an innovative healthcare software payment platform has never been greater. As a result, Waystar is poised to continue to deliver an attractive combination of revenue growth at scale and compelling adjusted EBITDA margins."

Second Quarter 2024 Financial Highlights

  • Revenue of $234.5 million, up 20% year-over-year
  • Net loss of $27.7 million, GAAP net income per share of $(0.21), and net loss margin of (11.8)%
  • Non-GAAP net income of $5.0 million and non-GAAP net income per share of $0.04
  • Adjusted EBITDA of $93.9 million and Adjusted EBITDA margin of 40%
  • Cash flow from operations of $15.5 million and Unlevered Free Cash Flow of $50.3 million

Key Metrics

  • 1,117 clients contributed over $100,000 in LTM revenue, up 9% year-over-year
  • A net revenue retention rate (NRR) of 108%

Financial Outlook

As of August 7, 2024, Waystar provides the following guidance for its full fiscal year 2024.1

  • Total revenue is expected to be between $902 million and $918 million
  • Adjusted EBITDA is expected to be between $360 million and $368 million
  • Non-GAAP net income is expected to be between $36 million and $42 million
  • Diluted non-GAAP net income per share is expected to be between $0.23 and $0.27

Webcast Information

Waystar's financial results will be discussed on a conference call scheduled at 4:30 p.m. Eastern Time today, August 7, 2024. A live audio conference call will be available on Waystar's website at https://investors.waystar.com/news-events/events. The webcast will be archived on the site for those unable to listen in real-time. This earnings release and the related Current Report on Form 8-K filed August 7, 2024 can be accessed on the Investor Relations page of the company's website. We routinely post important information on our website, including corporate and investor presentations and financial information. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included in the Investor Relations section of our website. Accordingly, investors should monitor this portion of our website, in addition to following our press releases, U.S. Securities and Exchange Commission ("SEC") filings, and public conference calls and webcasts.

Non-GAAP Financial Measures

To supplement the consolidated financial statements prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this press release contains certain non-GAAP financial measures as defined below. We present non-GAAP financial measures as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP. We believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate, and capital investments. Management uses Adjusted EBITDA and Adjusted EBITDA margin to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone provide.

Adjusted EBITDA, Adjusted EBITDA margin, non-GAAP net income, non-GAAP net income per share and unlevered free cash flow are not recognized terms under GAAP and should not be considered as an alternative to net income (loss) or net income (loss) margin as measures of financial performance or cash provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management's discretionary use, as they do not consider certain cash requirements such as interest payments, tax payments, and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. A reconciliation is provided below for our non-GAAP financial measures to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

The following non-GAAP financial measures and key performance metrics are defined below:

Adjusted EBITDA and Adjusted EBITDA Margin

We define Adjusted EBITDA as net loss before interest expense, net income tax benefit, depreciation and amortization, and as further adjusted for stock-based compensation expense, acquisition and integration costs, asset and lease impairments, costs related to amended debt agreements, and IPO-related costs. Adjusted EBITDA margin represents Adjusted EBITDA as a percentage of revenue.

Non-GAAP Net Income and Non-GAAP Net Income Per Share

We define non-GAAP net income as GAAP net income excluding the impact of stock-based compensation, acquisition and integration costs, asset and lease impairments, IPO-related costs, and costs related to amended debt agreements. The tax effects of the adjustments are calculated using a management-estimated annual effective non-GAAP tax rate of 21%.

We define non-GAAP net income per share as non-GAAP net income (loss) divided by weighted-average shares used to compute net loss per share.

Unlevered Free Cash Flow

We define unlevered free cash flow as cash from operations plus cash interest expense less capital expenses.

Net Debt

We define net debt as the sum of the current portion of long-term debt, long-term debt, and accounts receivable securitization less cash and equivalents.

Adjusted Net Leverage Ratio

We define adjusted net leverage ratio as net debt divided by adjusted EBITDA over the preceding twelve months.

Key Performance Metrics

Net Revenue Retention Rate

Our Net Revenue Retention Rate compares twelve months of client invoices for our solutions at two period end dates. To calculate our Net Revenue Retention Rate, we first accumulate the total amount invoiced during the twelve months ending with the prior period-end or Prior Period Invoices. We then calculate the total amount invoiced to those same clients for the twelve months ending with the current period-end, or Current Period Invoices. Current Period Invoices are inclusive of upsell, downsell, pricing changes, clients that cancel or chose not to renew, and discontinued solutions with continuing clients. The Net Revenue Retention Rate is then calculated by dividing the Current Period Invoices by the Prior Period Invoices. Our total invoices included in the analysis are greater than 98% of reported revenue. We use Net Revenue Retention Rate to evaluate our ongoing operations and for internal planning and forecasting purposes. Acquired businesses are included in the last-twelve-month Net Revenue Retention Rate in the ninth quarter after acquisition, which is the earliest point that comparable post-acquisition invoices are available for both the current and prior twelve-month period.

Customer Count with >$100,000 of Revenue

We regularly monitor and review our count of clients who generate more than $100,000 of revenue.

Our count of clients who generate more than $100,000 of revenue is based on an accumulation of the amounts invoiced to clients over the preceding twelve months. The invoices for acquired clients are included starting in the first full calendar quarter after the date of acquisition.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current views with respect to, among other things, statements regarding Waystar's expectations relating to future operating results and financial position, including full year 2024, and future periods; anticipated future expenses and investments; our industry, business strategy, goals, and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity, and capital resources and other financial and operating information. Forward-looking statements include all statements that are not historical facts. These statements may include words such as "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek," "foreseeable," "outlook," the negative version of these words or similar terms and phrases to identify forward-looking statements in this press release, including the discussion of outlook for full fiscal year 2024.

The forward-looking statements contained in this press release are based on management's current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs, and projections will result or be achieved. The following factors are among those that may cause actual results to differ materially from the forward-looking statements: our operation in a highly competitive industry; our ability to retain our existing clients and attract new clients; our ability to successfully execute on our business strategies in order to grow; our ability to accurately assess the risks related to acquisitions and successfully integrate acquired businesses; our ability to establish and maintain strategic relationships; the growth and success of our clients and overall healthcare transaction volumes; consolidation in the healthcare industry; our selling cycle of variable length to secure new client agreements; our implementation cycle that is dependent on our clients' timing and resources; our dependence on our senior management team and certain key employees, and our ability to attract and retain highly skilled employees; the accuracy of the estimates and assumptions we use to determine the size of our total addressable market; our ability to develop and market new solutions, or enhance our existing solutions, to respond to technological changes, or evolving industry standards; the interoperability, connectivity, and integration of our solutions with our clients' and their vendors' networks and infrastructures; the performance and reliability of internet, mobile, and other infrastructure; the consequences if we cannot obtain, process, use, disclose, or distribute the highly regulated data we require to provide our solutions; our reliance on certain third-party vendors and providers; any errors or malfunctions in our products and solutions; failure by our clients to obtain proper permissions or provide us with accurate and appropriate information; the potential for embezzlement, identity theft, or other similar illegal behavior by our employees or vendors, and a failure of our employees or vendors to observe quality standards or adhere to environmental, social, and governance standards; our compliance with the applicable rules of the National Automated Clearing House Association and the applicable requirements of card networks; increases in card network fees and other changes to fee arrangements; the effect of payer and provider conduct which we cannot control; privacy concerns and security breaches or incidents relating to our platform; the complex and evolving laws and regulations regarding privacy, data protection, and cybersecurity; our ability to adequately protect and enforce our intellectual property rights; our ability to use or license data and integrate third-party technologies; our use of "open source" software; legal proceedings initiated by third parties alleging that we are infringing or otherwise violating their intellectual property rights; claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties; the heavily regulated industry in which we conduct business; the uncertain and evolving healthcare regulatory and political framework; healthcare laws and data privacy and security laws and regulations governing our processing of personal information; reduced revenues in response to changes to the healthcare regulatory landscape; legal, regulatory, and other proceedings that could result in adverse outcomes; consumer protection laws and regulations; contractual obligations requiring compliance with certain provisions of the Bank Secrecy Act and anti-money laundering laws and regulations; existing laws that regulate our ability to engage in certain marketing activities; our full compliance with website accessibility standards; any changes in our tax rates, the adoption of new tax legislation, or exposure to additional tax liabilities; limitations on our ability to use our net operating losses to offset future taxable income; losses due to asset impairment charges; restrictive covenants in the agreements governing our credit facilities; interest rate fluctuations; unavailability of additional capital on acceptable terms or at all; the impact of general macroeconomic conditions; actions of certain of our significant investors, who may have different interests than the interests of other holders of our securities; and each of the other factors discussed under the heading of "Risk Factors" in the Company's prospectus filed with the Securities and Exchange Commission (the "SEC") on June 7, 2024 and in other reports filed with the SEC, all of which are available on the Investor Relations page of our website at investors.waystar.com.

Any forward-looking statements made by us in this press release speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. You should not place undue reliance on our forward-looking statements. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by any applicable securities laws.

About Waystar

Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 18 of 22 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 5 billion healthcare payment transactions, including over $1.2 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.

   

1 We have not reconciled the forward-looking Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per share guidance included above to the most directly comparable GAAP measure because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are incentive compensation (including stock-based compensation), transaction-related expenses, and certain fair value measurements, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.

Waystar

Condensed Consolidated Statements of Operations

(in thousands, except for share and per share data)

(unaudited)

 
  

Three months ended June 30, 

 

Six months ended June 30, 

  

2024

 

2023

 

2024

 

2023

Revenue

 

$

234,543

 

$

195,969

 

$

459,335

 

$

387,052

Operating expenses

            

Cost of revenue (exclusive of depreciation and
     amortization expenses)

  

80,451

  

60,500

  

155,643

  

119,656

Sales and marketing

  

45,715

  

31,413

  

79,495

  

61,377

General and administrative

  

39,955

  

14,478

  

66,090

  

29,159

Research and development

  

15,901

  

8,249

  

26,221

  

16,575

Depreciation and amortization

  

44,276

  

44,140

  

88,450

  

88,106

    Total operating expenses

  

226,298

  

158,780

  

415,899

  

314,873

Income from operations

  

8,245

  

37,189

  

43,436

  

72,179

Other expense

            

Interest expense

  

(49,195)

  

(49,145)

  

(105,007)

  

(96,291)

Related party interest expense

  

(1,346)

  

(2,001)

  

(2,718)

  

(4,355)

Loss before income taxes

  

(42,296)

  

(13,957)

  

(64,289)

  

(28,467)

Income tax benefit

  

(14,611)

  

(3,147)

  

(20,672)

  

(7,034)

Net loss

 

$

(27,685)

 

$

(10,810)

 

$

(43,617)

 

$

(21,433)

Net Income per share:

            

Basic

 

$

(0.21)

 

$

(0.09)

 

$

(0.34)

 

$

(0.18)

Diluted

 

$

(0.21)

 

$

(0.09)

 

$

(0.34)

 

$

(0.18)

Weighted-average shares outstanding:

            

Basic

  

133,527,766

  

121,676,273

  

127,601,532

  

121,674,361

Diluted

  

133,527,766

  

121,676,273

  

127,601,532

  

121,674,361

Waystar

Condensed Consolidated Balance Sheets

(in thousands, except for share and per share data)

(unaudited)

 
  

June 30, 2024

 

December 31, 2023

  

(Unaudited)

  

Assets

      

Current assets

      

Cash and cash equivalents

 

$

68,375

 

$

35,580

Restricted cash

  

12,083

  

9,848

Accounts receivable, net of allowance of $5,204 at June 30, 2024 and
     $5,335 at December 31, 2023

  

147,966

  

126,089

Income tax receivable

  

11,181

  

6,811

Prepaid expenses

  

14,758

  

13,296

Other current assets

  

16,389

  

30,426

  Total current assets

  

270,752

  

222,050

Property, plant and equipment, net

  

63,035

  

61,259

Operating lease right-of-use assets, net

  

9,579

  

10,353

Intangible assets, net

  

1,108,776

  

1,186,936

Goodwill

  

3,030,013

  

3,030,013

Deferred costs

  

77,177

  

65,811

Other long-term assets

  

7,549

  

6,552

  Total assets

 

$

4,566,881

 

$

4,582,974

Liabilities and stockholders' equity

      

Current liabilities

      

Accounts payable

 

$

50,747

 

$

45,484

Accrued compensation

  

23,032

  

23,286

Aggregated funds payable

  

11,987

  

9,659

Other accrued expenses

  

11,298

  

10,923

Deferred revenue

  

10,320

  

10,935

Current portion of long-term debt

  

12,577

  

17,454

Related party current portion of long-term debt

  

332

  

529

Current portion of operating lease liabilities

  

4,711

  

4,398

Current portion of finance lease liabilities

  

862

  

821

  Total current liabilities

  

125,866

  

123,489

Long-term liabilities

      

Deferred tax liability

  

130,594

  

174,480

Long-term debt, net, less current portion

  

1,301,208

  

2,134,920

Related party long-term debt, net, less current portion

  

32,882

  

64,758

Operating lease liabilities, net of current portion

  

12,327

  

14,278

Finance lease liabilities, net of current portion

  

11,750

  

12,194

Deferred revenue–LT

  

5,878

  

6,173

Other long-term liabilities

  

278

  

2,750

  Total liabilities

  

1,620,783

  

2,533,042

Commitments and contingencies (Note 18)

      

Stockholders' equity

      

Preferred stock $0.01 par value - 100,000,000 and zero shares authorized
     as of June 30, 2024 and December 31, 2023, respectively; zero shares
     issued or outstanding as of June 30, 2024 and December 31, 2023,
     respectively

  

  

Common stock $0.01 par value - 2,500,000,000 and 227,000,000 shares
     authorized at June 30, 2024 and December 31, 2023, respectively;
     166,659,634 and 121,679,902 shares issued and outstanding at June 30,
     2024 and December 31, 2023, respectively

  

1,667

  

1,217

Additional paid-in capital

  

3,178,697

  

2,234,688

Accumulated other comprehensive income (loss)

  

11,126

  

15,802

Accumulated deficit

  

(245,392)

  

(201,775)

Total stockholders' equity

  

2,946,098

  

2,049,932

Total liabilities and stockholders' equity

 

$

4,566,881

 

$

4,582,974

Waystar

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

       
  

Six months ended June 30, 

  

2024

 

2023

Cash flows from operating activities

      

Net loss

 

$

(43,617)

 

$

(21,433)

Adjustments to reconcile net (loss) income to net cash provided by operating
     activities

      

Depreciation and amortization

  

88,450

  

88,106

Share-based compensation

  

39,497

  

4,298

Provision for bad debt expense

  

1,055

  

1,097

Loss on extinguishment of debt

  

19,016

  

Deferred income taxes

  

(42,377)

  

(26,111)

Amortization of debt discount and issuance costs

  

2,646

  

5,219

Other

  

(99)

  

Changes in:

      

Accounts receivable

  

(22,932)

  

(392)

Income tax refundable

  

(4,371)

  

4,351

Prepaid expenses and other current assets

  

(2,319)

  

(2,808)

Deferred costs

  

(10,945)

  

(7,548)

Other long-term assets

  

(442)

  

(293)

Accounts payable and accrued expenses

  

4,392

  

7,181

Deferred revenue

  

(910)

  

(469)

Operating lease right-of-use assets and lease liabilities

  

(864)

  

(789)

Other long-term liabilities

  

  

42

Net cash provided by operating activities

  

26,180

  

50,451

Cash flows from investing activities

      

Purchase of property and equipment and capitalization of internally developed
     software costs

  

(12,428)

  

(9,482)

Net cash used in investing activities

  

(12,428)

  

(9,482)

Cash flows from financing activities

      

Change in aggregated funds liability

  

2,327

  

1,150

Proceeds from equity offering, net of underwriting discounts

  

914,288

  

Payments of third-party IPO issuance costs

  

(1,982)

  

Repurchase of shares

  

(844)

  

(687)

Proceeds from exercise of common stock

  

(33)

  

283

Proceeds from issuances of debt, net of creditor fees

  

535,209

  

Payments on debt

  

(1,425,874)

  

(8,991)

Third-party fees paid in connection with issuance of new debt

  

(1,410)

  

Finance lease liabilities paid

  

(403)

  

(411)

Net cash provided by (used in) financing activities

  

21,278

  

(8,656)

Increase in cash and cash equivalents during the period

  

35,030

  

32,313

Cash and cash equivalents and restricted cash–beginning of period

  

45,428

  

72,636

Cash and cash equivalents and restricted cash–end of period

 

$

80,458

 

$

104,949

Supplemental disclosures of cash flow information

      

Interest paid

 

$

82,264

 

$

94,648

Cash taxes paid (refunds received), net

  

26,141

  

5,559

Non-cash investing and financing activities

      

Fixed asset purchases in accounts payable

  

363

  

420

Unpaid third-party IPO issuance costs

  

1,354

  

Reconciliation of Balance Sheet Cash Accounts to Cash Flow Statement

      

Balance sheet

      

Cash and cash equivalents

  

68,375

  

95,738

Restricted cash

  

12,083

  

9,211

Total

  

80,458

  

104,949

Waystar

 

Reconciliation of Adjusted EBITDA

 

(in thousands)

 

(unaudited)

 
  

Three months ended
June 30,

 
  

2024

  

2023

 

Net Loss

 

$

(27,685)

  

$

(10,810)

 

Interest expense

  

50,541

   

51,146

 

Income tax benefit

  

(14,611)

   

(3,147)

 

Depreciation and amortization

  

44,276

   

44,140

 

Stock-based compensation expense

  

36,969

   

2,148

 

Acquisition and integration costs

  

206

   

278

 

Costs related to amended debt agreements

  

2,368

   

-

 

IPO-related costs

  

1,841

   

3

 

Adjusted EBITDA

 

$

93,905

  

$

83,758

 
         

Revenue

  

234,543

   

195,969

 

Net loss margin

  

(11.8)

%

  

(5.5)

%

Adjusted EBITDA margin

  

40.0

%

  

42.7

%

Waystar

 

Reconciliation of Non-GAAP Operating Expenses

 

(in thousands)

 

(unaudited)

 
  

Three months ended
June 30,

 
  

2024

  

2023

 

Cost of revenue (exclusive of depreciation and amortization expenses)

 

$

80,451

  

$

60,500

 

Less:

        

Stock-based compensation expense

  

(1,739)

   

(130)

 

Acquisition and integration costs

  

-

   

-

 

IPO-related costs

  

(5)

   

-

 

Cost of revenue (exclusive of depreciation and amortization
expenses), adjusted

 

$

78,707

  

$

60,370

 
         

Sales and marketing

 

$

45,715

  

$

31,413

 

Less:

        

Stock-based compensation expense

  

(8,892)

   

(452)

 

Acquisition and integration costs

  

-

   

(1)

 

IPO-related costs

  

(235)

   

-

 

Sales and marketing, adjusted

 

$

36,588

  

$

30,960

 
         

General and administrative

 

$

39,955

  

$

14,478

 

Less:

        

Stock-based compensation expense

  

(20,672)

   

(1,264)

 

Acquisition and integration costs

  

(103)

   

(152)

 

Costs related to amended debt agreements

  

(2,368)

   

-

 

IPO-related costs

  

(1,592)

   

(3)

 

General and administrative, adjusted

 

$

15,220

  

$

13,059

 
         

Research and development

 

$

15,901

  

$

8,249

 

Less:

        

Stock-based compensation expense

  

(5,666)

   

(302)

 

Acquisition and integration costs

  

(103)

   

(125)

 

IPO-related costs

  

(9)

   

-

 

Research and development, adjusted

 

$

10,123

  

$

7,822

 
         

Income tax benefit

 

$

(14,611)

  

$

(3,147)

 

Tax effect of adjustments

  

8,691

   

510

 

Income tax benefit, adjusted

 

$

(5,920)

  

$

(2,637)

 

Waystar

 

Reconciliation of Non-GAAP Net Income

 

(in thousands, except share and per share amounts)

 

(unaudited)

 
  

Three months ended
June 30,

 
  

2024

  

2023

 

Net Loss

 

$

(27,685)

  

$

(10,810)

 

Stock-based compensation expense

  

36,969

   

2,148

 

Acquisition and integration costs

  

206

   

278

 

Costs related to amended debt agreements

  

2,368

   

-

 

IPO-related costs

  

1,841

   

3

 

Tax effect of adjustments

  

(8,691)

   

(510)

 

Non-GAAP net income/(loss)

 

$

5,008

  

$

(8,891)

 
         

Non-GAAP net income/(loss) per share, basic

  

0.04

   

(0.07)

 

Non-GAAP net income/(loss) per share, diluted

  

0.04

   

(0.07)

 
         

Weighted-average shares used in computing basic non-GAAP net income
per share

  

133,527,766

   

121,676,273

 

Weighted-average shares used in computing diluted non-GAAP net
income per share

  

137,294,656

   

121,676,273

 

Waystar

 

Reconciliation of Unlevered Free Cash Flow

 

(in thousands)

 

(unaudited)

 
  

Three months ended
June 30,

 
  

2024

  

2023

 

Net cash provided by operating activities

 

$

15,450

  

$

33,593

 

Interest paid

  

41,751

   

47,910

 

Purchase of property and equipment and capitalization of internally developed software costs

  

(6,868)

   

(4,712)

 

Unlevered free cash flow

 

$

50,333

  

$

76,791

 

Waystar

 

Reconciliation of Net Debt

 

(in thousands)

 

(unaudited)

 
  

June 30,
2024

  

June 30,
2023

 

First lien term loan facility outstanding debt, current

 

$

12,909

  

$

17,983

 

First lien term loan facility outstanding debt, net of current portion

  

1,277,991

   

2,189,824

 

Receivables facility outstanding debt

  

70,000

   

50,000

 

Cash and cash equivalents

  

(68,375)

   

(95,738)

 

Net debt

 

$

1,292,525

  

$

2,162,069

 
         

Trailing twelve months adjusted EBITDA

 

$

353,900

  

$

318,380

 
         

Adjusted gross leverage ratio

  

3.8x

   

7.1x

 

Adjusted net leverage ratio

  

3.7x

   

6.8x

 

Media Contact
Kristin Lee 
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact
Sandy Draper
This email address is being protected from spambots. You need JavaScript enabled to view it.
502-238-9511 

Stock Quote

Last Trade: US$27.72
Daily Change: 0.30 1.09
Daily Volume: 599,666
Market Cap: US$4.620B

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB